These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32048215)

  • 1. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
    Marshall R; Atuah KN; Tekumalla SH
    Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
    Permanand G; Mossialos E; McKee M
    Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
    Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How does a new medicine reach the patient?].
    Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
    Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Management Plans in the European Union: Nonclinical Aspects.
    Baldrick P; Reeve L
    Ther Innov Regul Sci; 2016 Jan; 50(1):101-105. PubMed ID: 30236018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More medicines for children: impact of the EU paediatric regulation.
    Nordenmalm S; Tomasi P; Pallidis C
    Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.